Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
about
Expression of androgen receptor splice variants in prostate cancer bone metastases is associated with castration-resistance and short survivalPotential molecular targeting of splice variants for cancer treatmentEmerging data on androgen receptor splice variants in prostate cancerAdvances in hormonal therapies for hormone naïve and castration-resistant prostate cancers with or without previous chemotherapy20(S)-protopanaxadiol-aglycone downregulation of the full-length and splice variants of androgen receptor.Getting personal with prostate cancer: adding new pieces to an incomplete jigsaw puzzle.Androgen receptor splice variants activating the full-length receptor in mediating resistance to androgen-directed therapy.Androgen receptor and its splice variants in prostate cancerSplicing variants of androgen receptor in prostate cancer.Berberine suppresses androgen receptor signaling in prostate cancer.20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer.Methylselenocysteine preventing castration-resistant progression of prostate cancerVersatile pathway-centric approach based on high-throughput sequencing to anticancer drug discovery.Decoding the androgen receptor splice variants.Systematic structure modifications of multitarget prostate cancer drug candidate galeterone to produce novel androgen receptor down-regulating agents as an approach to treatment of advanced prostate cancer.mTOR signaling mediates resistance to tankyrase inhibitors in Wnt-driven colorectal cancer.Monensin, a polyether ionophore antibiotic, overcomes TRAIL resistance in glioma cells via endoplasmic reticulum stress, DR5 upregulation and c-FLIP downregulation.JBIR-120: a new growth inhibitor of hormone-refractory prostate cancer cells.Triggering of Suicidal Erythrocyte Death by the Antibiotic Ionophore Nigericin.Targeting Splicing in Prostate Cancer.
P2860
Q21091046-18DEA3ED-4C0B-4F17-AEB0-B54C02CA14ACQ27008529-C0DA16CF-B992-4349-93FE-5B4D220E4881Q28077830-3D3F9937-F781-44BE-86B2-68516D0F8024Q28829239-E78B2056-59B1-4815-B6EE-D105B6201CEFQ30528764-B1D69E4D-0DC2-47B0-ACB1-E74D6CFDA169Q33351113-53A915AF-901F-4D5C-B777-DB0AB1CCAE17Q33688956-45BFE673-8172-4CDE-AD4F-50097CD0E1EEQ34199684-9D55D212-B912-425C-A192-4E0A4B704C9EQ34448143-2A92A378-1AF3-4165-AD75-D18E49FCCF29Q35159508-D3470492-1162-4622-A4FC-88268120E979Q35399276-F9C2B562-8201-4EAD-B7A8-04A6643D45C0Q35582612-0127BA55-3799-4A6D-84F5-5402389B1BD7Q35849603-895A952C-91DC-4465-8C8F-3DF693876AAEQ38263870-8AEAE8E6-445B-4404-9C0A-278FA86A836BQ38361928-F906E295-EF3E-4811-9BE6-73A0EC7CBFE0Q38700323-100D2D81-D8CF-4350-A79D-C46378F57562Q39161204-2B4503FE-2657-49C6-B11C-B9AEF236F56DQ39358660-F056AEB6-2B82-4090-A029-C8BDDCF9E773Q46656108-62F4E915-DE36-4908-898A-5EFEB3D611E4Q55128284-A5322D8F-DDA8-4FD9-9BD6-0ABE72A06EA1
P2860
Pharmacological targeting of constitutively active truncated androgen receptor by nigericin and suppression of hormone-refractory prostate cancer cell growth.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Pharmacological targeting of c ...... y prostate cancer cell growth.
@ast
Pharmacological targeting of c ...... y prostate cancer cell growth.
@en
type
label
Pharmacological targeting of c ...... y prostate cancer cell growth.
@ast
Pharmacological targeting of c ...... y prostate cancer cell growth.
@en
prefLabel
Pharmacological targeting of c ...... y prostate cancer cell growth.
@ast
Pharmacological targeting of c ...... y prostate cancer cell growth.
@en
P356
P1476
Pharmacological targeting of c ...... ry prostate cancer cell growth
@en
P2093
Sachiko Okabe
Tetsuo Mashima
P304
P356
10.1124/MOL.110.064790
P577
2010-08-13T00:00:00Z